Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial

Locally Advanced ◽

Phase 2 ◽

Double Blind ◽

Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer

BMC Cancer ◽

10.1186/1471-2407-11-349 ◽

2011 ◽

Vol 11 (1) ◽

Cited By ~ 60

Author(s):

Marcia S Brose ◽

Christopher M Nutting ◽

Steven I Sherman ◽

Young Kee Shong ◽

Johannes WA Smit ◽

...

Keyword(s):

Thyroid Cancer ◽

Radioactive Iodine ◽

Locally Advanced ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(14)60421-9 ◽

2014 ◽

Vol 384 (9940) ◽

pp. 319-328 ◽

Cited By ~ 675

Author(s):

Marcia S Brose ◽

Christopher M Nutting ◽

Barbara Jarzab ◽

Rossella Elisei ◽

Salvatore Siena ◽

...

Keyword(s):

Thyroid Cancer ◽

Radioactive Iodine ◽

Locally Advanced ◽

Phase 3 ◽

Double Blind

Randomized phase 2 trial of cediranib alone or cediranib plus lenalidomide in iodine 131-refractory differentiated thyroid cancer (DTC): A University of Chicago Phase 2 Consortium trial.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.6013 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 6013-6013 ◽

Cited By ~ 1

Author(s):

Jonas A. De Souza ◽

Theodore Karrison ◽

Bernadette Libao ◽

Francis P. Worden ◽

Monika Krzyzanowska ◽

...

Keyword(s):

Thyroid Cancer ◽

Phase 2 ◽

University Of Chicago ◽

Phase 2 Trial ◽

Iodine 131 ◽

Randomized Phase 2

Phase 2 Trial of Intensity-Modulated Radiation Therapy +/- Concurrent Doxorubicin for Patients With Locally Advanced or Recurrent Non-anaplastic Thyroid Cancer

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2017.06.1481 ◽

2017 ◽

Vol 99 (2) ◽

pp. E368

Author(s):

P.B. Romesser ◽

E. Sherman ◽

A. Shaha ◽

M. Sabra ◽

C. Sabol ◽

...

Keyword(s):

Radiation Therapy ◽

Thyroid Cancer ◽

Locally Advanced ◽

Intensity Modulated Radiation Therapy ◽

Anaplastic Thyroid Cancer ◽

Phase 2 ◽

Intensity Modulated ◽

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)70100-2 ◽

2015 ◽

Vol 16 (6) ◽

pp. 716-728 ◽

Cited By ~ 175

Author(s):

Michael R Migden ◽

Alexander Guminski ◽

Ralf Gutzmer ◽

Luc Dirix ◽

Karl D Lewis ◽

...

Keyword(s):

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Locally Advanced ◽

Phase 2 ◽

Double Blind ◽

Phase 2 Trial ◽

Metastatic Basal Cell Carcinoma ◽

Different Doses

Faculty Opinions recommendation of Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725503664.793539334 ◽

2017 ◽

Author(s):

David Leffell

Keyword(s):

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Locally Advanced ◽

Phase 2 ◽

Double Blind ◽

Phase 2 Trial ◽

Metastatic Basal Cell Carcinoma ◽

Different Doses

Randomized Double-Blind, Placebo-Controlled, Multicenter Phase 2 Trial of Selenomethionine as a Modulator of Efficacy and Toxicity of Chemoradiation in Locally-Advanced Squamous Cell Carcinoma of the Head and Neck

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2013.06.1234 ◽

2013 ◽

Vol 87 (2) ◽

pp. S466-S467 ◽

Cited By ~ 2

Author(s):

M.D. Mix ◽

M. Jameson ◽

M. Tills ◽

S. Dibaj ◽

A. Groman ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Locally Advanced ◽

Advanced Squamous Cell Carcinoma ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Multicenter Phase

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine‐refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment

Cancer ◽

10.1002/cncr.29395 ◽

2015 ◽

Vol 121 (16) ◽

pp. 2749-2756 ◽

Cited By ~ 90

Author(s):

Maria E. Cabanillas ◽

Martin Schlumberger ◽

Barbara Jarzab ◽

Renato G. Martins ◽

Furio Pacini ◽

...

Keyword(s):

Thyroid Cancer ◽

Clinical Outcomes ◽

Phase 2 ◽

Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30084-0 ◽

2017 ◽

Vol 18 (4) ◽

pp. 486-499 ◽

Cited By ~ 25

Author(s):

Gary Middleton ◽

Daniel H Palmer ◽

William Greenhalf ◽

Paula Ghaneh ◽

Richard Jackson ◽

...

Keyword(s):

Pancreatic Carcinoma ◽

Locally Advanced ◽

Phase 2 ◽

Double Blind ◽

Multicentre Phase ◽

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Yearbook of Paediatric Endocrinology ◽

10.1530/ey.17.14.9 ◽

2020 ◽

Author(s):

Harrison SA ◽

Bashir MR ◽

Guy CD ◽

Zhou R ◽

Moylan CA ◽

...

Keyword(s):

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Alcoholic Steatohepatitis ◽